Amsterdam, the Netherlands
argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced its first quarter 2025 financial results and provided a business update.
See where we started — and where we’re going — as we chart a new course together in immunology.
Get argenx news and updates right to your inbox
June 3, 2025
argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference
May 28, 2025
argenx Announces Results of Annual General Meeting of Shareholders
May 8, 2025
argenx Reports First Quarter 2025 Financial Results and Provides Business Update
May 6, 2025
argenx to Present at BofA Securities 2025 Health Care Conference
Get photos, fact sheets, illustrations and more.
Dare to do more with a thriving career at argenx.
Get the latest news and info via our social media channels.
If so, please confirm below to proceed to our U.S. product page. If not, return to our homepage.
You are now leaving this website to visit another argenx website
This link will take you to a site maintained by a third party, which is responsible for its contents.
This link will take you to a site maintained by a third party, which is responsible for its contents.This website is intended for EU healthcare professionals only.
Please share just a few pieces of information so we can tailor the updates we send to you.
Not interested. Maybe later
Thank you for joining us on our journey to co-create potential therapies for people with severe autoimmune diseases. Together we discover.
Close
Follow us
Get the latest news and info via our social media channels.